Distler, O;
Allanore, Y;
Denton, CP;
Kuwana, M;
Matucci-Cerinic, M;
Pope, JE;
Atsumi, T;
... Khanna, D; + view all
(2023)
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.
The Lancet Rheumatology
, 5
(11)
e660-e669.
10.1016/S2665-9913(23)00238-2.
Preview |
Text
BA22515 RISE SSc LTE_published-UCL upload.pdf - Published Version Download (1MB) | Preview |
Abstract
Background: The phase 2b Riociguat Safety and Efficacy in Patients with Diffuse Cutaneous Systemic Sclerosis (RISE-SSc) trial investigated riociguat versus placebo in early diffuse cutaneous systemic sclerosis. The long-term extension evaluated safety and exploratory treatment effects for an additional year. Methods: Patients were enrolled to RISE-SSc between Jan 15, 2015, and Dec 8, 2016. Those who completed the 52-week, randomised, parallel-group, placebo-controlled, double-blind phase were eligible for the long-term extension. Patients originally assigned to riociguat continued therapy (riociguat–riociguat group). Those originally assigned to placebo were switched to riociguat (placebo–riociguat group), adjusted up to 2·5 mg three times daily in a 10-week, double-blind dose-adjustment phase, followed by an open-label phase. Statistical analyses were descriptive. Safety including adverse events and serious adverse events was assessed in the long-term safety analysis set (all patients randomly assigned and treated with study medication in the double-blind phase who continued study medication in the long-term extension). The RISE-SSc trial is registered with ClinicalTrials.gov, NCT02283762. Findings: In total, 87 (72%) of 121 patients in the main RISE-SSc study entered the long-term extension (riociguat–riociguat, n=42; placebo–riociguat, n=45). 65 (75%) of 87 patients were women, 22 (25%) were men, and 62 (71%) were White. Overall, 82 (94%) of 87 patients in the long-term extension had an adverse event; most (66 [76%] of 87) were of mild to moderate severity, with no increase in pulmonary-related serious adverse events in patients with interstitial lung disease. Interpretation: No new safety signals were observed with long-term riociguat in patients with early diffuse cutaneous systemic sclerosis. Study limitations include the absence of a comparator group in this open-label extension study. Funding: Bayer and Merck Sharp & Dohme.
| Type: | Article |
|---|---|
| Title: | Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/S2665-9913(23)00238-2 |
| Publisher version: | https://doi.org/10.1016/S2665-9913(23)00238-2 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10181771 |
Archive Staff Only
 |
View Item |
